BUZZ-Tarsus rises as China approval unlocks $15 million milestone for eye drug

Reuters03-23
BUZZ-Tarsus rises as China approval unlocks $15 million milestone for eye drug

** Shares of drugmaker Tarsus Pharmaceuticals TARS.O rise 3.5% to $62.25

** Co says it will receive $15 mln milestone payment, after partner Grand Pharmaceutical Group wins Chinese approval for eye drug TP-03

** The drug, sold as Xdemvy in U.S., is approved in China to treat Demodex blepharitis, an eyelid condition caused by tiny mites that leads to itching and irritation

** Co says the drug is the first approved treatment for the disease in China

** Grand Pharma holds exclusive rights to develop and sell the drug in Greater China, including mainland China, Hong Kong, Macau and Taiwan

** Tarsus says over 40 mln people in the region are affected; co is also eligible for further regulatory and sales milestones and future royalties

** Shares up ~49% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment